Multiomics of HIV non-progressors reveals immunity behind AIDS evasion
A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...
pharmaphorum9h
Gilead's HIV success and controversy: Expanding access amid criticism
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Nature1d
Why a fortunate few don’t get ill after HIV infection
Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...
IDWeek 2024: Prevention and treatment for HIV – clinical trials and policy challenges
Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
News Medical2d
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
pharmaphorum3d
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Cervical Cancer: Know The Risks, Symptoms And Treatment Options In India
– 17% of global cervical cancer deaths, accounting for almost 77,348 deaths per year – Primarily, cervical cancer affects women aged between 15-44 in India as per the HPV information centre.
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Understanding cervical cancer in India: Prevention, symptoms, and treatment options
Cervical cancer, a key cause of cancer-related deaths among Indian women, can be prevented and cured through early screening ...